What is Fortress Biotech, Inc.'s current stock price?

Fortress Biotech, Inc. (FBIO) currently trades at USD 2.60. Track real-time price changes and historical performance on AllInvestView.

What sector is Fortress Biotech, Inc. in?

Fortress Biotech, Inc. operates in the Health Care sector. AllInvestView lets you analyze sector allocation across your entire portfolio.

Fortress Biotech, Inc.

🧾 Earnings Recap – Q3 2025

Journey Medical delivered robust performance in Q3 2025, achieving 21% year-over-year revenue growth, driven primarily by the strong uptake of its new oral treatment, EMROSI.

EMROSI contributed $4.9 million, showing a 75% revenue increase compared to Q2, with total prescriptions growing 146%.
Despite a 16% year-over-year decline in revenue for legacy products due to Accutane generic competition, overall product revenues grew by more than 16% year-over-year.
Operating expenses rose only 9%, highlighting effective expense management linked to EMROSI's launch and potential for sustainable EBITDA positivity in Q4.
Over 2,700 unique prescribers have adopted EMROSI, a 50% increase since the last earnings call, indicating strong market acceptance and growth potential.
The company has secured access for EMROSI across over 100 million of the 187 million commercial lives, with further GPO contracting expected.

View full recap page

Fortress Biotech, Inc. Analysis (FBIO)

United States Health Care Official Website Stock

Is Fortress Biotech, Inc. a good investment? Fortress Biotech, Inc. (FBIO) is currently trading at 2.60 USD. Market analysts have a consensus price target of 10.75 USD. This suggests a potential upside from current levels.

Earnings Schedule: Fortress Biotech, Inc. is expected to release its next earnings report on May 13, 2026. The market consensus estimate for Forward EPS is -1.76.

Investor FAQ

Does Fortress Biotech, Inc. pay a dividend?

No, it does not currently pay a dividend.

What asset class is Fortress Biotech, Inc.?

Fortress Biotech, Inc. is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.

When is the next earnings date?

The next earnings date is projected to be May 13, 2026. The company currently has a trailing EPS of -0.12.

Company Profile

Fortress Biotech, Inc., a biopharmaceutical company, engages in the development and commercialization of biopharmaceutical products. The company markets dermatology products, including Emrosi, a minocycline hydrochloride extended-release capsule for the treatment of rosacea; Qbrexza a medicated cloth towelette for primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug for severe recalcitrant nodular acne; Amzeeq, a topical formulation of minocycline for inflammatory lesions of non-nodular moderate to severe acne vulgaris; Zilxi for inflammatory lesions of rosacea; Exelderm, an antifungal cream and solution for topical use; Targadox, an oral doxycycline drug for therapy for severe acne; and Luxamend, a water-based emulsion to provide a moist healing environment for superficial wounds, minor cuts or scrapes, dermal ulcers, donor sites, sunburns, and radiation dermatitis. It also develops intravenous Tramadol for the treatment of post-operative acute pain; CUTX-101, an injection for Menkes disease; UNLOXCYT for metastatic cutaneous squamous cell carcinoma; Olafertinib for EGFR mutation-positive NSCLC; CAEL-101, a monoclonal antibody for amyloid light chain amyloidosis; and Triplex, a cytomegalovirus vaccine. In addition, the company's early-stage product candidates include Dotinurad for gout; MB-101 for glioblastoma; MB-108 for recurrent GBM; MB-109 for refractory glioblastoma and anaplastic astrocytoma; MB-106 for B-cell non-hodgkin lymphoma; AJ201, an androgen receptor degradation enhancer; and BAER-101, a positive allosteric modulator. Further, its preclinical product candidates comprise AAV-ATP7A and AVTS-001 gene therapies; CK-103 BET inhibitor; CEVA-D and CEVA-102; CK-302, an anti-GITR; CK-303, an anti-CAIX; and oligonucleotide platform. The company was formerly known as Coronado Biosciences, Inc. and changed its name to Fortress Biotech, Inc. in April 2015. Fortress Biotech, Inc. was incorporated in 2006 and is based in Bay Harbor Islands, Florida.

Split Date	Split Ratio to 1
Oct. 10, 2023	0.070000

Split Date

Split Ratio to 1

Oct. 10, 2023

0.070000

Fortress Biotech, Inc. FBIO Open Fortress Biotech, Inc. in new tab

Fortress Biotech, Inc.

Key Metrics

Growth

Estimates

DCF Valuation

DCF Assumptions

DCF Result

Explore Premium Features